LKPC(600789)

Search documents
鲁抗医药(600789) - 北京市通商律师事务所关于山东鲁抗医药股份有限公司2024年度向特定对象发行A股股票的补充法律意见书
2025-08-01 11:47
北京市通商律师事务所 关于山东鲁抗医药股份有限公司2024年度 向特定对象发行A股股票的 补充法律意见书 二〇二五年八月 中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2024 年度 向特定对象发行 A 股股票的 补充法律意见书 山东鲁抗医药股份有限公司: 北京市通商律师事务所(以下简称"本所")是具有中华人民共和国(为法律 意见书之目的,不包括香港特别行政区、澳门特别行政区和台湾地区,以下简称 "中国")法律执业资格的律师事务所。本所受山东鲁抗医药股份有限公司(以下 简称"鲁抗医药"、"发行人"、"公司"或"上市公司")委托,作为鲁抗医药 2 ...
鲁抗医药(600789) - 关于山东鲁抗医药股份有限公司向特定对象发行股票申请文件的审核问询函的回复(修订稿)
2025-08-01 11:45
证券代码:600789 证券简称:鲁抗医药 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 (修订稿) 保荐机构(主承销商) 7-1-1 | 1、关于募投项目 | 3 | | --- | --- | | 2、关于融资规模与效益测算 | 46 | | 3、关于经营情况 | 79 | | 4、关于销售费用 | 90 | | 5、其他 | 101 | 1、关于募投项目 根据申报材料,1)本次募投项目包括高端制剂智能制造车间建设项目、生物农药 基地建设项目、新药研发项目及补充流动资金。2)高端制剂智能制造车间建设项目拟 投产的产品品种共 21 个,覆盖糖尿病、高血脂和原发性高胆固醇血症、细菌感染等适 应症;生物农药基地建设项目拟生产品种中多杀霉素、大黄素甲醚已取得批准文号,反 式乌头酸现已启动新农药登记相关试验工作;新药研发项目拟投入三款 I 类创新药的研 发。 (北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层) 二〇二五年八月 上海证券交易所: 贵所于 2025 年 5 月 9 日出具的上证上审(再融资)〔2025〕137 号《关于山东鲁抗 医药股份有限公司向特 ...
鲁抗医药(600789) - 鲁抗医药关于向特定对象发行股票申请文件的审核问询函回复更新的提示性公告
2025-08-01 11:45
证券代码:600789 证券简称:鲁抗医药 公告编号:2025—035 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请文件的 审核问询函回复更新的提示性公告 1 山东鲁抗医药股份有限公司董事会 2025 年 8 月 2 日 2 公司收到《问询函》后,按照要求会同相关中介机构就《问询函》所列问题 进行了认真研究和逐项落实,根据相关要求对《问询函》有关问题进行了说明和 论证,同时对募集说明书等申请文件的部分内容进行了相应补充和修订,具体内 容详见公司于2025年6月18日、7月8日在上海证券交易所网站(www.sse.com.cn) 披露的相关文件。 根据上交所进一步审核意见,公司会同相关中介机构对部分回复内容进行了 补充与修订,具体内容详见公司于同日在上海证券交易所网站(www.sse.com.cn) 披露的《关于山东鲁抗医药股份有限公司向特定对象发行股票申请文件的审核问 询函的回复(修订稿)》等相关文件。 公司本次向特定对象发行股票事项尚需通过上交所审核,并获得中国证券监 督管理委员会(以下简称"中国证监会")同意注册的批复后方可实施,最终能 否通过上交所审核并获得中国证监会同意注册的批复及其时间尚存在 ...
公告精选:西藏旅游、南方路机等提示交易风险;中国石化预计上半年净利润同比下降…





Zheng Quan Zhi Xing· 2025-07-31 21:02
人民财讯7月31日电,【热点】 西藏旅游:如后续股票交易进一步出现重大异常 将依规申请停牌核查 9天8板南方路机:近期公司股票价格脱离公司基本面情况 工业富联:主要客户及主要产品均未发生重大变化 二连板英维克:已构建相对完整的液冷全链条技术、产品和解决方案的能力 二连板胜通能源:近期公司经营情况正常 内外部经营环境未发生重大变化 二连板奇正藏药:公司经营情况正常 内外部经营环境未发生重大变化 东芯股份:对外投资企业上海砺算的相关芯片产品不应用于大模型算力集群等相关场景 广生堂:公司股票可能存在股价大幅上涨后回落的风险 禾望电气:目前尚无HVDC产品 安凯微:将发布低功耗锁控SoC芯片 亚虹医药:APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获积极初步结果 国恩股份:全资子公司取得PEEK相关项目备案 行动教育:实控人提议实施中期分红 每10股派10元 【并购重组】 达瑞电子:拟以增资及股权收购方式取得维斯德80%股权 大胜达:拟受让泰国远东30%股权 【再融资】 奥士康:拟发行可转债不超过10亿元 用于高端印制电路板项目 思泉新材:拟定增募资不超4.66亿元 长华化学:拟定增募资不超过2.3 ...
鲁抗医药(600789) - 鲁抗医药关于控股子公司获得药品注册证书的公告
2025-07-31 10:01
证券代码:600789 证券简称:鲁抗医药 公告编号:2025-034 注册分类:化学药品 4 类 山东鲁抗医药股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏,并对其内容的真实性、准确性和完整性承担法律责任。 近日,山东鲁抗医药股份有限公司(以下简称"公司")控股子公司山东鲁 抗医药集团赛特有限责任公司(以下简称"赛特公司")收到国家药品监督管理 局颁发的关于盐酸伐地那非片(以下简称"该药品")的《药品注册证书》(批 件号:2025S02296),该药品是按照新注册分类 4 类获批的仿制药,视为通过仿 制药质量和疗效一致性评价。现将相关情况公告如下: 一、药品证书基本信息 药品名称: 盐酸伐地那非片 剂型: 片剂 规格:20mg(按 C₂₃H₃₂N6O₄S 计) 原药品批准文号:国药准字 H20254953 药品注册标准编号:YBH17022025 生产企业:山东鲁抗医药集团赛特有限责任公司 审批结论:根据《中华人民共和国药品管理法》及有关规定,经审查,本品 符合药品注册的有关要求,批准注册,发给药品注册证书。质量标准、说明 ...
鲁抗医药(600789)7月30日主力资金净流出5034.12万元
Sou Hu Cai Jing· 2025-07-30 15:37
Group 1 - The core viewpoint of the news is that Shandong Lukang Pharmaceutical Co., Ltd. has shown a mixed financial performance in the latest quarter, with a decline in total revenue but an increase in net profit [1] - As of July 30, 2025, the company's stock price closed at 10.59 yuan, down 1.3%, with a turnover rate of 7.03% and a trading volume of 631,900 hands, amounting to 672 million yuan [1] - The company's latest quarterly report indicates total operating revenue of 1.674 billion yuan, a year-on-year decrease of 6.95%, while net profit attributable to shareholders reached 78.5976 million yuan, a year-on-year increase of 16.77% [1] Group 2 - The company has a current ratio of 1.279, a quick ratio of 0.862, and a debt-to-asset ratio of 54.65% [1] - Shandong Lukang Pharmaceutical has made investments in 17 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 187 trademark registrations and 240 patents, along with 313 administrative licenses, indicating a strong intellectual property portfolio [2]
医药生物行业7月28日资金流向日报
Zheng Quan Shi Bao Wang· 2025-07-28 08:44
Market Overview - The Shanghai Composite Index rose by 0.12% on July 28, with 15 sectors experiencing gains, led by defense and non-bank financials, which increased by 1.86% and 1.51% respectively. The pharmaceutical and biological sector ranked third in terms of gains [1] - Conversely, the coal and steel sectors saw declines of 2.60% and 1.41% respectively [1] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 18.575 billion yuan, with 8 sectors seeing net inflows. The electronics sector led with a net inflow of 3.655 billion yuan and a daily increase of 1.10%, followed by the communications sector with a net inflow of 2.848 billion yuan and a daily increase of 1.24% [1] - In contrast, 23 sectors faced net outflows, with the computer sector leading at a net outflow of 6.892 billion yuan, followed by the non-ferrous metals sector with a net outflow of 3.254 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector increased by 1.47% with a net inflow of 314 million yuan. Out of 474 stocks in this sector, 265 rose, 9 hit the daily limit up, while 191 fell, with 2 hitting the daily limit down [2] - Notably, 178 stocks in this sector experienced net inflows, with 8 stocks seeing inflows exceeding 100 million yuan. The top stock for net inflow was Heng Rui Medicine, with an inflow of 1.256 billion yuan, followed by Lu Kang Medicine and Zhong Sheng Pharmaceutical with inflows of 181 million yuan and 169 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Heng Rui Medicine: +10.00% with a turnover rate of 2.56% and a main fund flow of 1.255 billion yuan - Lu Kang Medicine: +4.30% with a turnover rate of 15.05% and a main fund flow of 181 million yuan - Zhong Sheng Pharmaceutical: +7.88% with a turnover rate of 11.59% and a main fund flow of 169 million yuan [3] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Changshan Pharmaceutical: -0.28% with a main fund outflow of 122.818 million yuan - Shenzhou Cell: -1.14% with a main fund outflow of 102.235 million yuan - WuXi AppTec: +3.08% with a main fund outflow of 94.187 million yuan [4]
鲁抗医药(600789) - 2025 Q2 - 季度业绩预告
2025-07-14 09:15
[Current Period Performance Forecast](index=1&type=section&id=Current%20Period%20Performance%20Forecast) The company forecasts a 59.34%-65.98% year-on-year decrease in H1 2025 net profit attributable to shareholders, primarily due to prior year non-recurring gains, while core business profitability shows growth 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (million CNY) | Year-on-Year Change | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of the Parent Company** | 102.06 - 121.96 | ↓ 59.34% - 65.98% | | **Net Profit Excluding Non-Recurring Gains/Losses** | 94.88 - 107.68 | ↑ 3.49% - 17.45% | - The performance forecast data represents preliminary calculations by the finance department and has not been audited by a certified public accountant[3](index=3&type=chunk) [Prior Period Operating Performance and Financial Status](index=1&type=section&id=Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) Key financial data for H1 2024, including approximately **300 million CNY** in net profit attributable to shareholders and **92 million CNY** in net profit excluding non-recurring items, serves as the baseline for current period comparisons H1 2024 Operating Performance | Metric (H1 2024) | Amount (million CNY) | | :--- | :--- | | **Net Profit Attributable to Shareholders of the Parent Company** | 299.96 | | **Net Profit Excluding Non-Recurring Gains/Losses** | 91.68 | | **Earnings Per Share** | 0.33 (CNY) | [Key Reasons for Current Period Performance Change](index=1&type=section&id=Key%20Reasons%20for%20Current%20Period%20Performance%20Change) The significant year-on-year decline is primarily due to a substantial **156 million CNY** non-recurring gain from land disposal in the prior year, with core business profit growing after excluding this impact - Non-recurring gains/losses impact: A **156 million CNY** asset disposal gain from the South Plant land transfer in the prior year significantly skewed the net profit base for comparison[6](index=6&type=chunk) - Core business impact: The company achieved increased operating profit year-on-year by strengthening excellent performance management and optimizing production, sales, and supply chain processes for quality and efficiency improvements[6](index=6&type=chunk) [Risk Warning](index=2&type=section&id=Risk%20Warning) The company confirms no significant uncertainties affecting the accuracy of this performance forecast exist as of the announcement date - As of the announcement date, the company confirms no significant uncertainties affecting the accuracy of this performance forecast[7](index=7&type=chunk) [Other Explanatory Notes](index=2&type=section&id=Other%20Explanatory%20Notes) The company reminds investors that this disclosure contains preliminary data, with final financial figures subject to the official 2025 semi-annual report, and advises caution regarding investment risks - This forecast data represents preliminary results, with final accurate figures subject to the company's officially disclosed 2025 semi-annual report[8](index=8&type=chunk)
“反式乌头酸微生物绿色制造技术”获2024年省技术发明一等奖
Qi Lu Wan Bao Wang· 2025-07-14 05:36
Core Viewpoint - The collaboration between Qingdao Institute of Bioenergy and Process Research and Shandong Lukang Pharmaceutical has successfully developed a microbial green manufacturing technology for trans-aconitic acid, overcoming production challenges and achieving large-scale production, which has been recognized with a first-class award in Shandong Province for 2024 [1][3][12] Group 1: Production Challenges and Solutions - Trans-aconitic acid is a food additive with significant applications in agriculture, medicine, and chemicals, but traditional production methods face high costs and inefficiencies [3][9] - The research team developed an integrated technology system using industrial Aspergillus niger as a chassis cell, enabling the conversion of starch sugars into trans-aconitic acid through synthetic biology [3][5] - Key challenges addressed include the genetic modification of industrial strains, achieving high-efficiency synthesis, and optimizing fermentation processes for industrial application [5][7] Group 2: Industrial Application and Market Potential - The successful production of trans-aconitic acid opens up new avenues for its use as a biopesticide, particularly in combating root-knot nematodes in agriculture, aligning with national green agriculture initiatives [9][11] - In the chemical industry, trans-aconitic acid is being developed into a bio-based plasticizer, providing a safer alternative to petroleum-based phthalate plasticizers, which are facing regulatory restrictions due to health concerns [11][12] - The technology has garnered attention from various enterprises, leading to successful production demonstrations and positioning trans-aconitic acid as a key bio-based chemical in the upcoming 2024-2027 development plan for fine chemical industries [12]
医药生物行业周报(7月第2周):创新药商保目录申报启动-20250714
Century Securities· 2025-07-14 01:01
Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].